Navigation Links
The Neuropathy Association's Scientific Research Grants Focus: Autoimmune and Chemotherapy-Induced Neuropathies
Date:11/10/2008

NEW YORK, Nov. 10 /PRNewswire-USNewswire/ -- The Neuropathy Association has announced two awardees for its annual Scientific Research Grants Program.

Every year, The Neuropathy Association--a national patient-based non-profit organization dedicated to finding a cure for neuropathy--awards two scientific research grants, each for $80,000 over a two-year period.

This year's grant recipients--Gary J. Bennett, Ph.D. of McGill University (Quebec, Canada) and Helene Bour-Jordan, Ph.D. and co-principal investigator, Mark S. Anderson, M.D., Ph.D. of the University of California, San Francisco (UCSF) Diabetes Center--were chosen from eleven applicants involved in neuropathy research at medical institutions across North America.

Dr. Bennett's proposal, Mechanism of Paclitaxel-Evoked Peripheral Neuropathy, is based on data suggesting that paclitaxel (Taxol(R)) causes neuropathy by a novel and previously unrecognized mechanism. Paclitaxel is used by tens of thousands of patients as a first-line drug in the treatment of ovarian, breast and non-small cell lung cancer. The neuropathy, a serious side-effect of paclitaxel, can be severe---and often painful---thus preventing or limiting the use of the drug as an effective chemotherapeutic and leading to a decline in the patient's quality of life.

Dr. Bennett adds, "Preventing and controlling the neuropathy resulting from paclitaxel will, in turn, allow us to administer larger doses to more effectively kill cancer cells and save lives."

With their proposal, Identification of Neural Autoantigens in Autoimmune Peripheral Neuropathy, Drs. Bour-Jordan and Anderson hope to identify proteins of the peripheral nervous system that are targeted by the immune system in autoimmune neuropathy.

Dr. Bour-Jordan explains, "Autoantibodies in tissue-specific autoimmune diseases are excellent indicators of disease and are instrumental in identifying major autoantigens that are now used in clinical trials
'/>"/>

SOURCE The Neuropathy Association
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. ReBuilder Medical Technologies, Inc. Contracts with ETS to Manufacture the Newest Version of its ReBuilder Neuropathy Treatment Device; Expects Sales to Increase 30%
2. Patient Enrollment Completed in Phase IIb Trial of EpiCept(TM) NP-1 in Diabetic Peripheral Neuropathy
3. Current and Emerging Therapies Have No Advantage Over Pfizers Lyrica in Their Effect on Patients Quality of Life in the Treatment of Diabetic Neuropathy
4. The Neuropathy Association Featured on NBCs Today Show as Part of National Neuropathy Week
5. The cause of all hereditary sensory and autonomic neuropathy type II cases has been established
6. Researchers provide genetic associations from a genome-wide scan for cardiovascular disease traits
7. Salugen to Present Research on Generational Associations of Reward Deficiency Syndrome at XVth World Congress on Psychiatric Genetics
8. Pharmacist Associations Partner to Increase the Voice of Pharmacy
9. Major Associations Band Together to Urge Congressional Action on Tobacco Legislation
10. American Heart Associations Announces Call for Entries for Howard L. Lewis Achievement Award
11. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2012)... randomized controlled trials (RCTs) are critical for determining ... Canada provides scant support for these studies compared ... CMAJ ( Canadian Medical Association Journal ... Hamilton Health Sciences, Hamilton, Ontario, with Dr. John ... analysis and appendix that Canada should provide better ...
(Date:5/22/2012)... , , TUESDAY, May 22 (HealthDay News) -- New research ... of snoring and daytime sleepiness, might also cut down ... -- the risk of developing high blood pressure. ... of high blood pressure in two groups with sleep ... CPAP, for either about four or 11 years. CPAP ...
(Date:5/22/2012)... uproar that began last year when the U.S. Preventive ... offer regular prostate-cancer tests to healthy men continued this ... Overall, they stuck to their guns, stating that a ... the PSA test, causes more harm than good ... dangerous, treatments. , But many people simply don,t believe ...
(Date:5/22/2012)... at Barrow Neurological Institute at St. Joseph,s Hospital ... the public perceives some magic tricks in recent ... tactics, marketing and sports. , Susana Martinez-Conde, PhD, ... Macknik, PhD, of Barrow,s Laboratory of Behavioral Neurophysiology ... and illusions. Their most recent original research projects, ...
(Date:5/22/2012)... HealthDay Reporter , , TUESDAY, May 22 ... no longer recommends that men routinely undergo prostate ... should ask their doctors for the exam if ... Urologists and cancer experts dismissed the idea that ... the PSA test will set a man,s personal ...
Breaking Medicine News(10 mins):Health News:Canada should significantly increase its funding of randomized clinical trials 2Health News:Sleep Apnea 'Mask' Might Also Help the Heart 2Health News:Sleep Apnea 'Mask' Might Also Help the Heart 3Health News:Sleep Apnea 'Mask' Might Also Help the Heart 4Health News:Psychological Science explains uproar over prostate-cancer screenings 2Health News:Barrow researchers use magic for discoveries 2Health News:Men Can Still Ask for PSA Test, and Some Should, Doctors Say 2Health News:Men Can Still Ask for PSA Test, and Some Should, Doctors Say 3
... scientists and clinicians to present advances,in CF research and ... meeting will draw more than 3,000 cystic fibrosis experts ... 3 - 6, 2007 to present the,latest information and ... The 21st annual North American Cystic Fibrosis Conference is ...
... Bristol-Myers Squibb,(NYSE: BMY ) announced today that ... Development organization as senior vice president, External,Science, Technology ... Sigal,chief scientific officer and president, Research and Development. ... R&D organization at this critical,juncture for Bristol-Myers Squibb, ...
... leading cause of parasitic infections in U.S. , THURSDAY, ... genome of the intestinal parasite Giardia lamblia , ... in the United States. , That makes giardia the ... in the country, experts note. , People contract Giardia ...
... the United States have determined that young adolescents who see ... To combat smoking among youth, public health groups have called ... A new study from New Zealand, however, calls that strategy ... the intended effect of putting such movies out of reach ...
... ... Executives to Provide Leadership, CHICAGO, Sept. 27 ... investment firms, has established an,Advisory Board to provide unbiased ... business partnerships. John H. Driscoll,Alter+Care President, announced the Alter+Care ...
... Complicated daily regimens lower their quality of life, ... For some people with diabetes, the burden of adhering ... their diabetes-related health complications, a U.S. study finds. , ... 700 adults with type 2 diabetes. , As reported ...
Other Medicine News:Health News:Anaheim to Host World's Largest Cystic Fibrosis Medical Meeting 2Health News:Jeremy Levin Joins Bristol-Myers Squibb as Senior Vice President of External Science, Technology and Licensing 2Health News:Scientists Map Intestinal Bug's Genome 2Health News:R rating might be unlikely to affect teens exposure to smoking in movies 2Health News:Alter+Care Creates the Advisory Board 2Health News:Alter+Care Creates the Advisory Board 3Health News:For Some, Diabetes Care Worse Than Illness Itself 2
(Date:5/22/2012)... Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ), ... commercialization of products for central nervous system disorders, ... at the Society for Research on Biological Rhythms ... The first poster entitled Pleiomorphic Expression of ... insight into the challenges faced by individuals suffering ...
(Date:5/22/2012)... ALLEGAN, Mich., May 22, 2012  Perrigo Company ... final approval from the U.S. Food and Drug ... for butoconazole nitrate 2% vaginal cream, the generic ... submit a substantially complete ANDA with a paragraph ... marketing exclusivity. Perrigo is working exclusively with KV Pharmaceutical ...
(Date:5/22/2012)... Generics, a division of Prodigy Health Supplier Corporation ... generic equivalent of the branded drug Camptosar by ... Laboratories to develop a portfolio of oncology products. ... developed through the partnership that will add consistent ... market, which has experienced record levels of shortages ...
Breaking Medicine Technology:Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting 2Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting 3Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream 2Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream 3GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 1GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 2GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 3GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 4ULURU Inc Announces the Engagement of Gilford Securities Incorporated to Serve as the Companys Financial Advisor 18324 1ULURU Inc Announces the Engagement of Gilford Securities Incorporated to Serve as the Companys Financial Advisor 18324 2MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 1MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 2MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 3MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 4
... 24, 2007 - ImmunoGen, Inc.,(Nasdaq: IMGN), a biopharmaceutical ... Prodrug (TAP),technology, today announced that clinical findings for ... tumors are to be,reported at the 43rd American ... place June 1-5, 2007 in Chicago, IL., Trastuzumab-DM1 ...
... 2007 /PRNewswire/ -- With enormous,investments and the ... firms need to develop effective strategies for,communicating ... communication planning and execution will gain a ... research and consulting firm Best Practices, LLC,successful ...
Other Medicine Technology:ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds,for Solid Tumors Are to be Reported at ASCO 2ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds,for Solid Tumors Are to be Reported at ASCO 3Clinical Trial Excellence: Shaping Markets Through Early,Communication of Clinical Trial Data 2Clinical Trial Excellence: Shaping Markets Through Early,Communication of Clinical Trial Data 3
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
Medicine Products: